| Autor: |
Walker, John M., Cabilly, Shmuel, Renschler, Markus F., Dower, William J., Levy, Ronald |
| Zdroj: |
Combinatorial Peptide Library Protocols; 1998, p209-234, 26p |
| Abstrakt: |
B-cell lymphomas are malignancies of B-lymphocytes In most cases they express surface immunoglobulin receptors (sIgR) with an antigen binding site determined by the heavy and light chain variable regions. This antigen binding site of the sIgR is an ideal tumor marker since it is unique to the tumor cells and shared among all the tumor cells from each individual. It can thus be used as a target for immunotherapy. Indeed monoclonal antibodies raised against the antigen binding site ("idiotype") of the Ig receptor can arrest the growth of lymphoma cells in vitro (1) and can induce complete tumor regressions and durable remissions in patients with lymphoma (2,3) [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
